Axovant Sciences (NASDAQ:AXON)‘s stock had its “hold” rating reissued by Cowen in a research note issued to investors on Tuesday.
The analysts wrote, “We maintain our BUY rating and $25 PT for SVRA shares.””
Other research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a research note on Thursday, October 19th. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Wednesday, January 31st. BidaskClub raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 12th. Finally, Piper Jaffray Companies reissued a “hold” rating on shares of Axovant Sciences in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $13.61.
A number of institutional investors and hedge funds have recently bought and sold shares of AXON. BlackRock Inc. grew its holdings in Axovant Sciences by 99.8% in the 4th quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock valued at $15,347,000 after buying an additional 1,454,454 shares during the period. OxFORD Asset Management LLP grew its holdings in Axovant Sciences by 842.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after buying an additional 777,505 shares during the period. Eagle Asset Management Inc. purchased a new stake in Axovant Sciences in the 3rd quarter valued at about $4,471,000. Hudson Bay Capital Management LP purchased a new stake in Axovant Sciences in the 4th quarter valued at about $1,845,000. Finally, Artal Group S.A. grew its holdings in Axovant Sciences by 185.7% in the 3rd quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $3,440,000 after buying an additional 325,000 shares during the period. Institutional investors own 96.82% of the company’s stock.
WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/13/axovant-sciences-axon-rating-reiterated-by-cowen.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.